Although sales and marketing and office based activities are perceived as having fewer EHS hazards and risks than research and development or manufacturing, lost time injury and illness is a major concern in our commercial organization. The key health and safety risks that must be managed in a commercial setting are driver safety, emergency planning (especially fire and first aid), ergonomics, mental well-being and resilience and accident investigation and reporting.
The environmental issues most relevant to Commercial are the proper management of energy and waste and the design and labeling of products and packaging. Programs are being developed to help the commercial businesses implement EHS programs that address their particular risks and issues. Through collaboration with the Group Internal Audit and Corporate Ethics and Compliance departments, a detailed picture of how EHS is being addressed in Commercial is being compiled.
The key areas being examined are environment, health and safety policies; documented responsibilities for implementing EHS policies and procedures; identification and assessment of EHS risks and issues; waste management, recycling and product returns; ergonomics (in particular, computer workstation use); occupational travel (including driving on company business); fire and first aid; emergency response planning; adverse events investigation and reporting. 6. Identify if the workers are given Personal Protective Equipment (PPE) while working.
Name them. Answer: This section defines the requirements for the use of personal protective equipment to control or eliminate hazards or exposure to illness or injury. Unless otherwise noted, contractors are to provide the required and needed personal protective equipment, medical clearance, and the training described in this section and is responsible for the compliance of their employees. The contractor’s safety manager will make regular field inspections to verify compliance.
The contractor’s designated safety representative will review personal protective equipment to ensure that only equipment complying with OSHA, ANSI, NIOSH, and MSHA regulations or this manual is used. A contract employee who refuses to use the prescribed personal protective equipment or will fully damages this equipment will be subject to the disciplinary procedures outlined in Section 3. Contract employees must be trained on the use, inspection, care, and storage of all personal protective equipment.
Body harnesses, shock absorbent lanyards, and self-retracting lifelines, regardless of configuration, must be subjected to a documented monthly inspection by the contractor. Inspection records are to be maintained by the contractor so that they are available upon request to appropriate GSK representatives. 4. An acceptable method of inspection includes marking for harness and lanyard monthly inspections using the colour code, Monthly Inspection Colour Code Chart. The tape must be placed around the “D” ring located in the middle of the back on the harness and the shock absorber ends of lanyards.
5. In addition to monthly inspections, the contractor is expected to conduct additional inspections in accordance with regulatory requirements. According to OSHA standard 1926. 502(d) (21), personal fall arrest systems shall be inspected prior to each use for wear, damage, and other deterioration, and defective components shall be removed from service. vi. Footwear 1. Employees must wear shoes or boots. Sandals, open-toe shoes, and bare feet are prohibited in project and non-public areas.
Contractors must ensure that the appropriate protective footwear is worn by employees in areas where safety shoes signs are posted and in areas where workers are exposed to foot injuries due to falling or rolling objects, objects piercing the sole, or where workers’ feet are exposed to electrical hazards. All personnel in construction and demolition areas are required at all times to wear safety footwear meeting the ANSI Standard Z41-1999 requirements for toe-cap protection. Appropriate foot protection must be worn for operating tamping equipment and when handling and carrying heavy tools or objects.
vii. Hand and Skin Protection 1. Wear appropriate hand protection when handling objects or substances that could cut, burn, injure the hand, or be absorbed into the skin, and when exposed to harmful temperature extremes. 2. Wear fully buttoned lab coats, hairnets, and beard covers in designated areas (available at entries to these areas). Certain areas require a higher level of protection in the form of coveralls or air suits. Do not enter these areas without appropriate clearance, training, and protection. 3. Shirts with sleeves must be worn at all times.
4. Shorts are prohibited in project and non-public areas. viii. Welding, Cutting, and Burning 1. Wear a welding helmet with welding hood (combination hard hat) when welding. Soft caps are prohibited. 2. Face shields or goggles that fit on hard hats must be worn along with approved safety glasses during grinding operations. 3. For overhead work, wear fire-resistant hard hats and fire-retardant shoulder covers. 4. Keep clothing free of oil, grease, and flammable material. Button collars and cuffs, and turn pant cuffs inside pants.
Pockets must be covered with flaps and buttoned, or removed from the front of vests, shirts, and aprons. 5. Welders and their helpers must wear gloves and proper infrared/ultraviolet eye protection in addition to safety glasses. 6. Workers engaged in oxy-acetylene welding or cutting must wear a welding helmet or safety goggles that are equipped with suitable filter lenses. 7. Workers who are engaged in electric arc welding must use shields or helmets that are equipped with suitable filter lenses that fit on a hard hat. 8. Wear approved safety glasses or goggles under a combination hard hat or welding hood.
9. Do not perform welding, burning, or open flame work on staging suspended by fibre or synthetic rope. Additional Personal Protective Equipment The contractor must furnish any additional equipment required by unusual circumstances (such as high temperature work or handling corrosive liquids) and not specifically covered in this section. Use of such must be reviewed with the GSK representative. 7. Identify how the company promotes safety and health in the workplace. Answer: This is how GSK promoting the safety and health in the workplace through some programs that has been done the research on it.
i. Hazard Assessment and Communication GlaxoSmithKline assesses environment, health and safety (EHS) hazards associated with the research, development and manufacture of our products in order to meet ethical, producer responsibility and regulatory requirements and to ensure the workplace is safe and the environment is unharmed. In 2004, we focused on new pharmaceuticals in research and development and continued to refine and use an innovative, tiered approach to assess environment, health and safety hazards for GlaxoSmithKline materials.
This approach has been integrated into the research and development process in order to identify EHS hazards for chemicals at early stages of product development according to the potential risk of environmental or worker exposure. We also systematically assess flammability and possible adverse health or environmental effects. Occupational and Environmental Exposure Limits GlaxoSmithKline develops occupational and environmental exposure limits for our materials in order to guide the design and selection of chemical control systems to protect our employees’ health and the environment.
During 2004, our experts established new occupational exposure limits for more than 40 materials and environmental limits for more than 300 materials. These limits are established based on data from extensive testing of the materials. EHS Information for Formulated Products GlaxoSmithKline has developed Safety Data Sheets (SDSs) for more than 1,200 of its pharmaceutical, biological and consumer healthcare products that are either in R&D or are sold in many major global markets. These SDSs are available throughout the company.
In addition, approximately 300 of these SDSs for US marketed products and 350 for UK marketed products are available externally on gsk. com for direct access by external customers. In order to support new product development, triggers are built into R&D procedures to ensure SDSs are created for new products as they progress through the development process. The objective is to make SDSs available to provide EHS information in support of clinical and consumers studies and follow through to product launch. EHS Hazard Information on GlaxoSmithKline Materials
GlaxoSmithKline uses a global intranet system called [email protected] to provide EHS hazard information in a unified format to all operations. This system provides safety data sheets (SDS) and related information for GlaxoSmithKline materials and products and for key manufacturing and process chemicals. The information for GlaxoSmithKline materials and products, available in English, French, German, Italian, Portuguese and Spanish, is updated regularly with new information available to the company worldwide by the day after the update.
In 2004, extensive resource was dedicated to materials in research and development to ensure adequate information is available to support new products. Additional tools were developed to better manage the overwhelming amount of EHS information. For example, an email notification tool was added, enabling employees to be kept up-to-date with SDS changes automatically. ii. Safe Transport of Materials Research and manufacture of pharmaceuticals involves transporting various chemical, biological and radioactive materials and products around the world.
To ensure compliance with national and international transportation laws and conventions and to safeguard employees, the public and the environment, GlaxoSmithKline employs site-based transport safety advisors and specialists in business units that transport materials and products. Over 250 advisors in 40 countries participate in a global network that supports continuous improvement by sharing technical and regulatory information, best practices and lessons learned. In May 2004, CEHS launched the Haz Class(tm) System.
This is a centralized material hazard information and classification system that provides hazard information, classification support, and transportation guidance, tracking and emergency information for hazardous materials shipments worldwide. It currently has more than 600 users at 57 sites, and supports transportation of more than 10,000 shipments of materials per month. In September 2004, the annual Dangerous Goods Advisor Safety Forum was held in Hamburg, Germany. The two-day forum provided an opportunity for dangerous goods experts from throughout Europe to share best practices and lessons learned.
Environmental Controls Air GlaxoSmithKline identifies, characterizes and assesses emissions to the air from our operations so that we can minimize or manage them in a way that eliminates adverse impact to the public or the environment. As part of our program to reduce air emissions, especially greenhouse gases, wind turbines were installed at one of our manufacturing sites and are planned for another. In addition to reducing greenhouse gas, these turbines will have the benefit of generating renewable energy for our operations.
We have achieved significant reductions in solvent releases through reformulation of final dosage forms using water-based technologies. iv. Ergonomics Reducing ergonomic illness and injury continues to be a key area of focus through Operational Excellence initiatives, business objectives, local consultation, site audits and global training. The Office Ergonomics Self-Assessment web-based tool, which is now active in multiple languages, is well established in Corporate Headquarters locations and is being used in several facilities across the globe.
The concept and value of Participatory Ergonomic Improvement teams has been demonstrated at pilot sites and has been built into the company ergonomic risk reduction strategy. Regional focus groups composed of EHM and EHS professionals have worked to create and share good ergonomic practices and solutions. A musculoskeletal gap analysis tool has been developed and will be used extensively in 2005 to facilitate management of the impact of musculoskeletal injury and illness on employees and the business, from both occupational and non-occupational factors.
An initiative is underway to identify employee musculoskeletal risk factors from our general Health Risk Appraisal (HRA) tool and link employees to risk reduction programs and web-based educational materials. To ensure the Employee Health Management groups have the right expertise, a full-time professional ergonomist has been recruited to lead development of the ergonomic strategy and a significant number of occupational health advisers have enrolled in training courses in ergonomics.
These efforts have and will continue to reduce the impact of ergonomic illness and injury and will form the focus of our continued programs. In alignment with our workplace ergonomics programs, we are addressing the management of non-occupational illness and promoting fitness in our workforce. This effort includes wellness programs, standardized approaches to case management of employees with ergonomic illness or injury, proactive rehabilitation including access to physiotherapy, workplace adaptation and changing behaviors and beliefs of employees and their medical providers.
Tools and educational material to assist sites with managing these issues are contained in the GSK musculoskeletal gap analysis tool and will be promoted and used throughout 2005. v. Occupational Hygiene and Control of Chemical Exposures GlaxoSmithKline’s current portfolio of pharmaceutical and consumer healthcare products is extensive and requires sites to control many chemicals used in synthesis and final products to ensure that employees are protected.
In addition to existing products, GSK has a strong pipeline of new products some of which bring challenges due to high potency with low occupational exposure levels (OELs) and increased manufacturing complexity. To manage these potential exposure issues, GSK has been focusing on chemical agent exposure for several years and will continue to do so in 2005. GSK has a strategy for addressing the challenge of chemical exposures and for meeting our 2010 aspiration to achieve a ‘shirt sleeve’ workplace.